A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02988960 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 12, 2016
Last Update Posted : February 14, 2023
|
Sponsor:
AbbVie
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumors Cancer | Drug: ABBV-927 Drug: ABBV-181 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 163 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors |
| Actual Study Start Date : | February 22, 2017 |
| Estimated Primary Completion Date : | February 10, 2024 |
| Estimated Study Completion Date : | February 10, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Escalating Arm 1: ABBV-927
Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
|
Drug: ABBV-927
Intravenous |
|
Experimental: Escalating Arm 2: ABBV-927
Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
|
Drug: ABBV-927
Intratumoral |
|
Experimental: Escalating Arm 3: ABBV-927+ABBV-181
Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
|
Drug: ABBV-927
Intravenous Drug: ABBV-181 Intravenous
Other Name: Budigalimab |
|
Experimental: Escalating Arm 4: ABBV-927+ABBV-181
Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
|
Drug: ABBV-927
Intratumoral Drug: ABBV-181 Intravenous
Other Name: Budigalimab |
|
Experimental: Escalating Arm 5 (Japan): ABBV-927
Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
|
Drug: ABBV-927
Intravenous |
|
Experimental: Escalating Arm 6 (Japan): ABBV-927+ABBV-181
Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
|
Drug: ABBV-927
Intravenous Drug: ABBV-181 Intravenous
Other Name: Budigalimab |
|
Experimental: Expansion Arm A: ABBV-927
Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
|
Drug: ABBV-927
Intravenous |
|
Experimental: Expansion Arm B: ABBV-927+ABBV-181
Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
|
Drug: ABBV-927
Intratumoral Drug: ABBV-181 Intravenous
Other Name: Budigalimab |
|
Experimental: Expansion Arm C: ABBV-927+ABBV-181
Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
|
Drug: ABBV-927
Intravenous Drug: ABBV-181 Intravenous
Other Name: Budigalimab |
Primary Outcome Measures :
- Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 [ Time Frame: Up to 8 weeks ]The MTD and the RPTD of ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 will be determined during the dose escalation phase of the study. Once the RPTD has been determined, the dose expansion portion will begin.
- Time to Cmax (Tmax) of ABBV-927 [ Time Frame: Up to 12 weeks after participant's first dose ]Time to Cmax (Tmax) of ABBV-927.
- Maximum observed serum concentration (Cmax) of ABBV-927 [ Time Frame: Up to 12 weeks after participant's first dose ]Maximum observed serum concentration (Cmax) of ABBV-927.
- Terminal-Phase Elimination Rate Constant (β) of ABBV-927 [ Time Frame: Up to 12 weeks after participant's first dose ]Terminal-phase elimination rate constant (β)of ABBV-927.
- Terminal half-life (t1/2) of ABBV-927 [ Time Frame: Up to 4 weeks after participant's first dose ]Terminal half-life (t1/2) of ABBV-927.
- Area under the serum concentration-time curve (AUCt) of ABBV-927 [ Time Frame: Up to 12 weeks after participant's first dose ]Area under the serum concentration-time curve from time zero to the time of last measurable concentration (AUCt) of ABBV-927.
- Time to Cmax (Tmax) of ABBV-181 [ Time Frame: Up to 12 weeks after participant's first dose ]Time to Cmax (Tmax) of ABBV-181.
- Maximum observed serum concentration (Cmax) of ABBV-181 [ Time Frame: Up to 12 weeks after participant's first dose ]Maximum observed serum concentration (Cmax) of ABBV-181.
- Terminal-Phase Elimination Rate Constant (β) of ABBV-181 [ Time Frame: Up to 12 weeks after participant's first dose ]Terminal-phase elimination rate constant (β)of ABBV-181.
- Terminal half-life (t1/2) of ABBV-181 [ Time Frame: Up to 4 weeks after participant's first dose ]Terminal half-life (t1/2) of ABBV-181.
- Area under the serum concentration-time curve (AUCt) of ABBV-181 [ Time Frame: Up to 12 weeks after participant's first dose ]Area under the serum concentration-time curve from time zero to the time of last measurable concentration (AUCt) of ABBV-181.
- Number of Participants with Adverse Events [ Time Frame: Up to 30 days after and up to 24-month of treatment period ]An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Secondary Outcome Measures :
- Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment) [ Time Frame: Up to 30 days after and up to 24-month of treatment period ]CBR defined as the proportion of subjects with a confirmed partial response (PR), complete response (CR), or stable disease for at least 24 weeks to the treatment.
- Duration of objective response (DOR) [ Time Frame: Up to 30 days after and up to 24-month of treatment period ]DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.
- Objective response rate (ORR) [ Time Frame: Up to 30 days after and up to 24-month of treatment period ]ORR is defined as the proportion of participants with a confirmed partial or complete response to the treatment.
- Progression-free survival (PFS) [ Time Frame: Up to 30 days after and up to 24-month of treatment period ]PFS time is defined as the time from the first dose of ABBV-927 to disease progression or death, whichever occurs first.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Participants have adequate bone marrow, kidney and liver function.
- Participants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to 45% within 28 days prior to the first dose of study drug.
- Participants must have creatinine clearance greater than or equal to 50 mL/min as measured by 24-hour urine or estimated by the Cockcroft-Gault formula.
- Participants must have total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times ULN.
- Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.
- Participants in all combination therapy arms must have recurrent or metastatic HNSCC or NSCLC and previously received platinum-based therapy and progressed either during or after anti-programmed death ligand 1 (PDL1)-based therapy. In addition, participants must have received only one prior immunotherapy.
- The Sponsor may decide to limit the specific tumor types selected or treatment settings for specific arms based on evidence gathered.
Exclusion Criteria:
- Participant must not have an active or prior documented autoimmune disease in the last 2 years.
- Participant must not have current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).
- Participant must not have a history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, previous clinical diagnosis of tuberculosis, inflammatory bowel disease, interstitial lung disease, or immune-mediated pneumonitis.
- Participant must not have a history of clinically significant uncontrolled condition(s) including but not limited to the following: uncontrolled hypertension; symptomatic congestive heart failure; unstable angina pectoris or cardiac arrhythmia including atrial fibrillation.
- Participant must not have a history of coagulopathy or a platelet disorder associated with significant clinical risk of thromboembolic event in the judgement of the investigator, or major thromboembolic event within 6 months prior to the first dose of study treatment.
- Participant must not have a prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis while receiving immunotherapy.
- Participant must not have a known uncontrolled malignancy of the central nervous system.
- Participants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy.
- Female participants must not be pregnant, breastfeeding or considering becoming pregnant during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
- Male participants must not be considering fathering a child or donating sperm during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
- Participant is judged by the investigator to have evidence of hemolysis.
- For Japan only, participants with a history of interstitial lung disease (pneumonitis) or current interstitial lung disease (pneumonitis).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02988960
Locations
Show 22 study locations
Sponsors and Collaborators
AbbVie
Investigators
| Study Director: | ABBVIE INC. | AbbVie |
| Responsible Party: | AbbVie |
| ClinicalTrials.gov Identifier: | NCT02988960 |
| Other Study ID Numbers: |
M15-862 2016-002219-16 ( EudraCT Number ) |
| First Posted: | December 12, 2016 Key Record Dates |
| Last Update Posted: | February 14, 2023 |
| Last Verified: | February 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by AbbVie:
|
Non-small cell lung cancer (NSCLC) Squamous cell carcinoma of the head and neck (SCCHN) Advanced solid tumor Cancer Pancreatic adenocarcinoma |
Cutaneous melanoma ABBV-927 ABBV-181 Budigalimab |
Additional relevant MeSH terms:
|
Neoplasms |